Joseph C. Scodari - 20 Apr 2026 Form 4 Insider Report for Acurx Pharmaceuticals, Inc. (ACXP)

Reporting relationship: Director
Issuer ticker: ACXP
Reported as of: 20 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Apr 2026, 16:19:03 UTC
Prior SEC filing: 08 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Kostantinos Skordalos, Power of Attorney For: Joseph C. Scodari

Key filing fact

Joseph C. Scodari filed Form 4 for Acurx Pharmaceuticals, Inc. (ACXP) on 22 Apr 2026.

Key facts

This page summarizes Joseph C. Scodari's Form 4 filing for Acurx Pharmaceuticals, Inc. (ACXP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 22 Apr 2026, 16:19.

Change

Previous filing in this sequence was filed on 08 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001319892 Primary reporting owner

Scodari Joseph C

Relationship: Director
Address: C/O ACURX PHARMACEUTICALS, INC.,, 259 LIBERTY AVENUE, STATEN ISLAND
Signature: /s/ Kostantinos Skordalos, Power of Attorney For: Joseph C. Scodari
Signature date: 22 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACXP transaction Derivative

Stock Option

Award

Transaction value
Shares: +2,150
Change %
Price: $0.000000^*
Shares after: 2,150
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,150
Exercise price: $2.36
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.